Compare SUVEN LIFE with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES DISHMAN PHARMA SUVEN LIFESCIENCES/
DISHMAN PHARMA
 
P/E (TTM) x 18.0 25.1 71.9% View Chart
P/BV x 3.7 3.3 109.2% View Chart
Dividend Yield % 0.6 0.7 86.9%  

Financials

 SUVEN LIFESCIENCES   DISHMAN PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
DISHMAN PHARMA
Mar-16
SUVEN LIFESCIENCES/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs338374 90.2%   
Low Rs169129 131.4%   
Sales per share (Unadj.) Rs52.1197.8 26.4%  
Earnings per share (Unadj.) Rs6.821.2 32.2%  
Cash flow per share (Unadj.) Rs8.634.7 24.7%  
Dividends per share (Unadj.) Rs1.502.00 75.0%  
Dividend yield (eoy) %0.60.8 74.4%  
Book value per share (Unadj.) Rs65.3179.9 36.3%  
Shares outstanding (eoy) m127.2880.69 157.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.91.3 382.3%   
Avg P/E ratio x37.111.9 312.8%  
P/CF ratio (eoy) x29.67.2 408.2%  
Price / Book Value ratio x3.91.4 277.6%  
Dividend payout %22.09.4 232.8%   
Avg Mkt Cap Rs m32,27220,306 158.9%   
No. of employees `0001.10.8 130.5%   
Total wages/salary Rs m6615,355 12.3%   
Avg. sales/employee Rs Th6,132.219,252.7 31.9%   
Avg. wages/employee Rs Th611.16,459.5 9.5%   
Avg. net profit/employee Rs Th803.52,064.1 38.9%   
INCOME DATA
Net Sales Rs m6,63515,961 41.6%  
Other income Rs m242265 91.3%   
Total revenues Rs m6,87716,226 42.4%   
Gross profit Rs m1,6044,103 39.1%  
Depreciation Rs m2211,091 20.3%   
Interest Rs m38944 4.0%   
Profit before tax Rs m1,5872,334 68.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m718624 115.1%   
Profit after tax Rs m8691,711 50.8%  
Gross profit margin %24.225.7 94.0%  
Effective tax rate %45.226.7 169.3%   
Net profit margin %13.110.7 122.2%  
BALANCE SHEET DATA
Current assets Rs m6,23211,018 56.6%   
Current liabilities Rs m1,4909,517 15.7%   
Net working cap to sales %71.59.4 760.0%  
Current ratio x4.21.2 361.3%  
Inventory Days Days86110 78.2%  
Debtors Days Days8335 237.1%  
Net fixed assets Rs m4,04316,304 24.8%   
Share capital Rs m127161 78.9%   
"Free" reserves Rs m8,18312,907 63.4%   
Net worth Rs m8,31014,516 57.2%   
Long term debt Rs m184,189 0.4%   
Total assets Rs m10,38929,805 34.9%  
Interest coverage x43.13.5 1,241.9%   
Debt to equity ratio x00.3 0.7%  
Sales to assets ratio x0.60.5 119.3%   
Return on assets %8.78.9 98.0%  
Return on equity %10.511.8 88.8%  
Return on capital %19.517.5 111.3%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m5,6224,952 113.5%   
Fx outflow Rs m1,799697 258.2%   
Net fx Rs m3,8224,255 89.8%   
CASH FLOW
From Operations Rs m3562,786 12.8%  
From Investments Rs m-279-1,529 18.2%  
From Financial Activity Rs m-225-941 23.9%  
Net Cashflow Rs m-148316 -46.8%  

Share Holding

Indian Promoters % 63.4 61.4 103.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 3.7 -  
FIIs % 0.0 12.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 22.1 165.2%  
Shareholders   37,287 46,261 80.6%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   GSK PHARMA  ASTRAZENECA PHARMA  BIOCON   IPCA LABS  NATCO PHARMA  

Compare SUVEN LIFESCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 93 Points Higher; Oil & Gas and Realty Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the oil & gas sector.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Oct 16, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS